Xenon Pharmaceuticals Inc. 8-K

What Happened

• Xenon Pharmaceuticals Inc. announced that its shareholders approved the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan at the company's annual meeting held on June 2, 2026. The 2026 Plan replaces the Amended and Restated Xenon Pharmaceuticals Inc. 2014 Equity Incentive Plan.
• The company filed the 2026 Equity Incentive Plan as Exhibit 10.1 to its Current Report on Form 8-K dated June 3, 2026. The Proxy Statement describing the principal features of the plan was filed on or after April 22, 2026.

Key Details

• Annual meeting date: June 2, 2026.
• Approved: Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan (replaces the 2014 Plan).
• Disclosure: Summary of plan terms in the Proxy Statement filed April 22, 2026 (or thereafter); full plan filed as Exhibit 10.1 to the 8-K.
• 8-K signed and filed June 3, 2026 by Thomas P. Kelly, Chief Financial Officer.

Why It Matters

• The new equity incentive plan sets the framework for future equity-based compensation (stock options, restricted stock, RSUs, etc.) for employees, directors and other service providers, replacing the prior 2014 plan.
• For investors, the plan matters because it enables future equity grants that can affect share count and dilution over time and is a key tool for management to attract and retain talent. The 8-K and the exhibit provide the definitive terms investors can review to assess potential dilution and grant mechanics.